Table 5.
Univariate analysis for the 1‐year LRFS, DMFS, PFS, and OS of 51 cases of HNS
| Factor | 1y LRFS | P value | 1y DMFS | P value | 1y PFS | P value | 1y OS | P value |
|---|---|---|---|---|---|---|---|---|
| Sex | 0.634 | 0.870 | 0.563 | 0.861 | ||||
| Male | 0.909 | 0.820 | 0.699 | 0.910 | ||||
| Female | 0.862 | 0.870 | 0.773 | 0.952 | ||||
| Age | 0.404 | 0.593 | 0.312 | 0.168 | ||||
| ≤40 | 0.920 | 0.849 | 0.805 | 0.955 | ||||
| >40 | 0.833 | 0.844 | 0.648 | 0.894 | ||||
| Clinical stage | 0.125 | 0.354 | 0.082 | 0.017 | ||||
| I ~ II | 0.958 | 0.875 | 0.833 | 1.0 | ||||
| III ~ IV + recurrent | 0.790 | 0.824 | 0.625 | 0.839 | ||||
| GTV volume* | 0.009 | 0.209 | 0.005 | 0.244 | ||||
| <38.54 cm3 | 0.955 | 0.863 | 0.818 | 0.944 | ||||
| ≥38.54 cm3 | 0.807 | 0.833 | 0.651 | 0.853 | ||||
| Pathology | 0.140 | 0.498 | 0.064 | 0.416 | ||||
| Chondrosarcoma | 0.897 | 0.844 | 0.791 | 0.941 | ||||
| Non‐chondrosarcoma | 0.874 | 0.849 | 0.698 | 0.920 | ||||
| Site | 0.435 | 0.247 | 0.057 | 0.906 | ||||
| Nasal cavity‐paranasal sinus | 0.929 | 0.673 | 0.612 | 0.900 | ||||
| Skull base | 0.878 | 0.878 | 0.816 | 0.938 | ||||
| Others | 0.862 | 0.941 | 0.757 | 0.944 | ||||
| Re‐radiotherapy | 0.007 | 0.150 | 0.001 | <0.001 | ||||
| Yes | 0.701 | 0.716 | 0.436 | 0.701 | ||||
| No | 0.936 | 0.884 | 0.812 | 1.0 | ||||
| Second primary | 0.021 | 0.965 | 0.066 | <0.001 | ||||
| Yes | 0.536 | 0.857 | 0.429 | 0.571 | ||||
| No | 0.910 | 0.846 | 0.789 | 1.0 | ||||
| PT beam types | 0.715 | 0.528 | 0.497 | 0.510 | ||||
| IMCT | 0.883 | 0.836 | 0.724 | 0.907 | ||||
| IMPT + IMCT | 0.875 | 0.875 | 0.750 | 1.0 | ||||
| IMPT | 1.0 | 1.0 | 1.0 | 1.0 |
Abbreviations: DMFS, distant metastasis‐free survival; LRFS, local recurrence‐free survival; OS, overall survival; PFS, progression‐free survival; PT, particle therapy.
*
The median volume of GTV was 38.54 cm3.